Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium bifidum bgn4 + bifidobacterium animalis subsp. lactis ad011 + lactobacillus acidophilus ad031
- Development stage
- Unknown
- Lead developer
- BIFIDO
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A probiotic combination consisting of three specific bacterial strains: *Bifidobacterium bifidum* BGN4, *Bifidobacterium animalis subsp. lactis* AD011, and *Lactobacillus acidophilus* AD031. Developed by BIFIDO Co., Ltd, this mixture is primarily used as a live biotherapeutic to modulate the immune system, specifically by promoting Th1-type immunity and regulatory T-cell responses. Clinical studies have demonstrated its efficacy in the primary prevention of eczema in high-risk infants when administered prenatally to mothers and postnatally to infants. It is also indicated for the relief of irritable bowel syndrome (IBS) symptoms and the prevention of allergic sensitization.
- Brand names
- ZIGUNUK Bifidus
- Other names
- Bifidobacterium bifidum BGN4 + Bifidobacterium lactis AD011 + Lactobacillus acidophilus AD031
Beyond the preview
Go deeper on bifidobacterium bifidum bgn4 + bifidobacterium animalis subsp. lactis ad011 + lactobacillus acidophilus ad031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium bifidum bgn4 + bifidobacterium animalis subsp. lactis ad011 + lactobacillus acidophilus ad031.